Author of

• 34780

  +

  P37 - Pathology - Biomarker Testing (ID 107)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 34812

    +

    P37.25 - Clinical Validation of Low-costs Next Generation Sequencing Panels in Solid Tumors (ID 2671)

    00:00 - 00:00  |  Presenting Author(s): Yen-Lin Chen
    • Abstract
    • Slides

    Introduction
    

    The implementation of personalized medicine has revolutionized the current strategies in oncology. Numerous comparisons of technology platforms for mutation testing conclude that the methods should offer high sensitivity, tissue economy and short turnaround time for physicians to guide treatment decisions. In the current study, we were trying to validate the low cost NGS panels in different solid tumors. In addition, validation sample tumors include lung cancers, colorectal cancers and thyroid cancers from both Taiwan and Vietnam.

    Methods
    

    A total of 180 tumor samples were retrospectively collected from Cardinal Tien Hospital (Taiwan) and Bach Mai Hospital (Vietnam) between 2015~2019. Thirty EGFR mutation positive non-small cell lung cancer (NSCLC) samples, thirty KRAS/NRAS mutation positive colorectal cancer (CRC) samples, and thirty BRAF mutation positive thyroid cancer (TC) samples were chosen from each hospital. All the mutations were tested by Sanger sequencing and NGS.

    Results
    

    There were 38 EGFR L858R mutation cases, 22 EGFR 19 deletion mutation cases, 2 EGFR T790M mutation cases, 29 KRAS G12D mutation cases, 24 KRAS G12V mutation cases, 5 KRAS G13C mutation cases, 2 NRAS G12S mutation cases, and 60 BRAF V600E mutation cases. The 2 EGFR T790M cases were also positive for the EGFR L858R mutation. The results were the same with Sanger sequencing which give the sensitivity, specificity, positive predict value and negative predict value to be 100%.

    Conclusion
    

    The low cost RaSeq^TM molecular testing system is an accessible, rapid, and reliable testing option for both routine and challenging FFPE specimens. It can serve well as a routine molecular diagnostic tool in most pathology laboratories. The high sensitivity and high accuracy with different gene tests simultaneously are the most advantage in the clinical cancer molecular diagnosis.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.